Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. “We feel ...

The withdrawal also comes after an Evotec spokesperson publicly commented that the company’s goal was to remain independent, Torley said. Mid-morning Friday, Evotec’s share price was down ...

Torley said bispecifics and monoclonal antibodies make up the largest slice of the conversations that Halozyme is having with potential customers, followed by small molecules and cell therapies.